Corpus overview


Overview

MeSH Disease

Human Phenotype

There are no HP terms in the subcorpus


Transmission

There are no transmission terms in the subcorpus


Seroprevalence
    displaying 1 - 1 records in total 1
    records per page




    Treatment of COVID-19 Patients with Convalescent Plasma SERO in Houston, Texas

    Authors: Eric Salazar; Katherine K. Perez; Madiha Ashraf; Jian Chen; Brian Castillo; Paul A. Christensen; Taryn Eubank; David W. Bernard; Todd N. Eagar; S. Wesley Long; Sishir Subedi; Randall J. Olsen; Christopher Leveque; Mary R. Schwartz; Monisha Dey; Cheryl Chavez-East; John Rogers; Ahmed Shehabeldin; David Joseph; Guy Williams; Karen Thomas; Faisal Masud; Christina Talley; Katharine G. Dlouhy; Bevin Valdez Lopez; Curt Hampton; Jason Lavinder; Jimmy D. Gollihar; Andre C. Maranhao; Gregory C. Ippolito; Matthew Ojeda Saavedra; Concepcion C. Cantu; Prasanti Yerramilli; Layne Pruitt; James M. Musser

    doi:10.1101/2020.05.08.20095471 Date: 2020-05-13 Source: medRxiv

    Background: COVID-19 disease, caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), has spread globally, and no proven treatments are available. Convalescent plasma SERO therapy has been used with varying degrees of success to treat severe microbial infections MESHD for more than 100 years. Methods: Patients (n=25) with severe and/or life-threatening COVID-19 disease were enrolled at the Houston Methodist hospitals from March 28 to April 14, 2020. Patients were transfused with convalescent plasma SERO obtained from donors with confirmed SARS-CoV-2 infection MESHD and had been symptom free for 14 days. The primary study outcome was safety, and the secondary outcome was clinical status at day 14 post-transfusion. Clinical improvement was assessed based on a modified World Health Organization 6-point ordinal scale and laboratory parameters. Viral genome sequencing was performed on donor and recipient strains. Results: At baseline, all patients were receiving supportive care, including anti-inflammatory and anti-viral treatments, and all patients were on oxygen support. At day 7 post-transfusion with convalescent plasma SERO, nine patients had at least a 1-point improvement in clinical scale, and seven of those were discharged. By day 14 post-transfusion, 19 (76%) patients had at least a 1-point improvement in clinical status and 11 were discharged. No adverse events as a result of plasma SERO transfusion were observed. The whole genome sequencing data did not identify a strain genotype-disease severity correlation. Conclusions: The data indicate that administration of convalescent plasma SERO is a safe treatment option for those with severe COVID-19 disease. Randomized, controlled trials are needed to determine its efficacy.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.